The latest health news
Biogen on Thursday mounted a vigorous defense of its controversial Alzheimer’s drug, Aduhelm, with the company’s head of research and development releasing an open letter to the Alzheimer’s community that …
Read More
Who’s going to run the FDA? Why isn’t the Biden administration leakier? And what if Aduhelm isn’t a blockbuster after all? We cover all that and more this week on …
Read More
WASHINGTON — Acting Food and Drug Administration Commissioner Janet Woodcock acknowledged on Wednesday her agency may have misstepped in its handling of its polarizing approval of a new Alzheimer’s drug. …
Read More
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox. It’s official: Medicare …
Read More
WASHINGTON — Two powerful House Democrats on Monday demanded documents from Biogen about the approval process, marketing, and pricing of its controversial new Alzheimer’s drug. The letter is the latest …
Read More
The head of the Food and Drug Administration has called for a wide-ranging federal investigation into the approval of Biogen’s treatment for Alzheimer’s disease just one month after a decision …
Read More
How worrying is the Delta variant? Is there a digital health bubble? And what is going on at the FDA? We cover all that and more this week on “The …
Read More
WASHINGTON — Former health secretary Donna Shalala called for a federal investigation into the Food and Drug Administration’s polarizing approval of a Biogen treatment for Alzheimer’s disease, citing STAT’s revelation …
Read More
For families and physicians grappling with the historic approval this month of the controversial Alzheimer’s drug Aduhelm, there’s no shortage of unanswered questions. But a critical one has largely been …
Read More